PetVivo (PETV) Q3 2026 earnings summary

Executive summary

• Achieved significant progress in strategic alliances, including exclusive licensing agreements for AI veterinary software with Digital Landia and VetStem, and expanded collaborations with Veterinary Growth Partners and Piezo BioMembrane.

• Launched PetVivo AI, an AI-powered SaaS platform for veterinarians, and AgenticPet B2C AI solution, both showing strong early adoption and reducing customer acquisition costs by up to 90%.

• Advanced commercialization of flagship products Spryng and PrecisePRP, with growing adoption in North America, Europe, and Mexico, and received Health Canada recognition for Spryng.

• Strengthened board with appointment of Josh Ruben, bringing expertise in healthcare, finance, and capital markets.

• Operates as a single segment with a pipeline of animal health products and 19 patents protecting its technology.

Financial highlights

• Nine-month revenues totaled $887,000, down 2% year-over-year, with Q3 revenue at $286,108; Spryng sales were $400,800 and PrecisePRP at $486,000.

• Gross profit for nine months was $551,500 (62.2% margin), down from $812,130 (89% margin) last year due to higher PrecisePRP sales.

• Operating expenses for nine months were $6.7 million; operating loss was $6.1 million.

• Net loss for nine months was $7.5 million (27 cents/share), compared to $6 million (30 cents/share) last year.

• Cash and equivalents at period end were $18,164; net cash used in operations was $5.3 million.

Outlook and guidance

• Management expects continued sales momentum and market penetration in fiscal 2026 and beyond, with new product launches and expanded international presence.

• No formal revenue or P&L guidance provided; management aims to drive adoption of both Spryng and PrecisePRP.

• Anticipate revenue from Digital Landia and VetStem partnerships to begin in the next fiscal year.

• Continued need for additional capital to support commercialization and operations.